Jiangwei Wu

Jiangwei Wu

Auto-generated profile, based on publicly available information

Jiangwei Wu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BLBoya Liao
Boya Liao
KLKin-Ho Aaron Lee
Kin-Ho Aaron Lee
FMFei Meng
Fei Meng
JWJiangwei Wu
Jiangwei Wu
JYJinghan Yang
Jinghan Yang
Sau Ching Stanley WONGSau Ching Stanley WONG
Sau Ching Stanley WONG
Cardiac pain is difficult to diagnose and treat in part because existing models fail to capture human neuro-cardiac signaling. This review examines how iPSC-derived cardiomyocytes and sensory neurons in co-culture and organoid systems model ischemic and neuro-immune mechanisms, and how such platforms enable regenerative and neuromodulatory translation. We identify key barriers (maturation, heterogeneity, scalability, safety) and propose priorities to bridge discovery and clinical application.

Verified
Journal Article
Open access
PDF file
BLBoya Liao
Boya Liao
ALAaron Kin-Ho Lee
Aaron Kin-Ho Lee
ZGZheng Gu
Zheng Gu
FMFei Meng
Fei Meng
JWJiangwei Wu
Jiangwei Wu
Sau Ching Stanley WONGSau Ching Stanley WONG
Sau Ching Stanley WONG
Cardiac-related pain, including angina pectoris and pain accompanying myocardial infarction, remains clinically important, and existing treatments are inadequate for some patients. Animal and primary-tissue studies provide important mechanistic evidence, but species differences and limited access to patient-matched human neuro-cardiac tissue constrain translation. This review synthesizes the following separate advances relevant to future human iPSC-based cardiac-pain modeling: molecular mechanisms that may be reconstructed in vitro; platforms ranging from two-dimensional cultures to proposed sensory-innervated three-dimensional and microfluidic systems; and potential applications in target validation, patient-specific modeling, and analgesic screening. We distinguish direct human iPSC evidence from findings obtained in animal, primary-cell, cardiac-only, autonomic-neuron, or non-cardiac pain models. We also discuss maturation, standardization, and regulatory challenges. iPSC technologies may complement existing models and support mechanism-focused, patient-stratified research, but direct validation in human sensory–neuron–cardiac systems remains limited.